EX-99.1 2 a2024q3earningsreleaseex991.htm EX-99.1 Document

附錄99.1
avantorlogoa08.jpg
avantor®報告2024年第三季度業績

•網絡銷售額達17.1億美元，下降0.3％；有機下降0.7％
•凈利潤為5780萬美元；調整後的EBITDA為30250萬美元
•稀釋後的GAAP每股收益為0.08美元；調整後每股收益為0.26美元
•營運現金流為$24480萬; 自由現金流為$20400萬
2024年10月25日，位於賓夕法尼亞州RADNOR。 紐交所:AVTR的領先全球貨幣，為生命科學和愛文思控股行業的客戶提供至關重要的產品和服務，今天公佈了截至2024年9月30日的第三財季財務業績。
“我們的團隊交出了又一個穩健的財務業績季報告，包括在生物加工方面的表現超越以及實驗室解決方案部門回歸增長。我們對於營運資金的紀律性處理導致又一個業內最佳的自由現金流轉換率季度，我們也提高了本年度的自由現金流指引，” Michael Stubblefield，總裁兼首席執行官說。
「我們進入第四季度時，將繼續按計劃實現生物加工業務中高位數成長，這得益於訂單的持續增長勢頭。我們的成本轉型計劃進展順利，我們具有良好的立足點，能夠實現全年指引。展望未來，我們將繼續專注於為 Avantor 實現長期增長，為客戶和股東帶來差異化價值，」Stubblefield 總結道。
2024年第三季度
2024年9月30日結束的三個月內，淨銷售額為171440萬美元，較2023年第三季度下降0.3%。外幣兌換對有正面影響0.4%，導致在有機基礎上銷售下降0.7%。
凈利潤由2023年第三季度的10840萬美元下降至5780萬美元，經過調整的凈利潤則從可比前期的17160萬美元增至17520萬美元。凈利潤率為3.4%。經調整後的EBITDA為30250萬美元，調整後的EBITDA毛利率為17.6%。經調整後的營運收入為27480萬美元，調整後的營運收入毛利率為16.0%。
每股收益在按照GAAP計算的稀釋基礎上為0.08美元，而調整後每股收益為0.26美元。
營運現金流為$24480萬，而自由現金流為$20400萬。截至2024年9月30日，調整後淨槓桿率為3.8倍。
2024年第三季度 - 分部業績
實驗室解決方案
•凈銷售額達到117150萬美元，按照報告比2023年第三季度的115910萬美元增長了1.1%。銷售在有機基礎上增長了0.6%。
•調整後營業收入為$15150萬，相較於可比較的上一期的$15910萬。調整後營業收入利潤率為12.9%。


生物科技生產
•净销售额为54290万美元，较2023年第三季度的56110万美元下降了3.2％。销售额按有机方式下降了3.5％。
•調整後的營業收入為13810萬元，而在可比的前一期為14820萬元。調整後的營業收入利潤率為25.4%。
調整後的營運收入是avantor的業務部門報告盈利能力衡量指標，根據廣泛接受的會計原則，並被管理層用來衡量和評估我們公司的業務部門表現。
看漲會議通話
我們將於今天，2024年10月25日上午8時（美東時間）舉行一場討論我們業績的電話會議。現場網路轉播和簡報，以及重播將在該網站上提供。 Avantor網站的投資者專區將提供現場網路轉播和簡報。.
關於avantor
avantor® 我們是領先的生命科學工具公司和全球貨幣提供商，為生命科學和愛文思控股行業提供使命關鍵產品和服務。我們與客戶並肩工作，協助在科學旅程的每一步實現醫學、醫療保健和科技的突破。我們的產品組合在幾乎所有最重要的研究、開發和生產活動的各個階段中被使用，在180個國家的超過30萬客戶地點。欲獲取更多資訊，請訪問 avantorsciences.com 並找到我們 LinkedIn, X（Twitter） 及 Facebook.
使用非GAAP財務指標
為了評估我們的表現，我們監控許多關鍵因數。必要時，我們會補充根據美國通用會計原則（"GAAP"）確定的業務運作結果，以一些我們認為對投資者、債權人和其他人評估我們的表現有用的非GAAP財務指標。這些因數不應僅獨立考慮或作為報告的GAAP結果的替代，因為它們與類似的GAAP指標相比可能包括或排除某些項目，這些指標可能與其他公司報告的相同標題指標不可比較。相反，應將這些因數視為查看我們業務方面的額外方式，這樣可以更全面地了解我們的業務。我們強烈建議投資者全面審閱我們向美國證券交易委員會提交的報告中包含的綜合基本報表，而不僅僅依賴於任何單一財務指標或通訊。
本新聞稿使用的非依照普通會計準則的財務指標包括有機基礽下的銷售增長（下降）、調整後營業收入、調整後營業收入率、調整後息稅折舊及攤銷前利潤（EBITDA），調整後息稅折舊及攤銷前利潤率，調整後凈利潤，調整後每股收益，調整後淨槓桿率，自由現金流及自由現金流轉換率。
•有機淨銷售增長（下滑）排除我們報告的淨銷售變動受去年收購和出售的收益以及外幣匯率變動影響。我們認為這個衡量指標對投資者很有用，可以一致地衡量和評估我們各業務部門和報告期間的基本商業運營表現。我們的管理層出於同樣的原因使用這個指標。
•調整後的營運收益是指我們的淨利潤或虧損，經過以下項目的調整：(i) 利息費用、(ii) 所得稅費用、(iii) 取得無形資產的攤銷、(iv) 債務抹銷損失、(v) 與特定資產減損相關的費用、(vi) 及


特定其他調整。調整後的營業利潤率是根據 GAAP 確定的淨銷售收入除以調整後的營業收入。我們認為這些衡量指標對投資者是有用的，因為這些方式可以在所呈現的時間段中持續分析我們業務的潛在趨勢。我們的管理層也出於同樣原因使用這些衡量指標。此外，根據 GAAP，調整後的營業收入是我們的業務部門報告的盈利能力指標。
•调整後的息稅折舊及攤銷前利潤（Adjusted EBITDA）是我們的凈利潤或虧損，經過以下項目的調整：（i）利息開支、（ii）所得稅費用、（iii）獲得之無形資產攤銷、（iv）折舊費用、（v）償還債務產生的虧損、（vi）與特定資產減損相關的費用、（vii）和某些其他調整。調整後的息稅折舊及攤銷前利潤率是根據GAAP確定的淨銷售額除以調整後的息稅折舊及攤銷前利潤。我們認為這些指標對投資者很有用，可以分析我們業務的基本趨勢，在呈現的各期間之間保持一致。我們的管理層出於同樣的原因使用這些指標。
•Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) losses on extinguishment of debt, (iii) charges associated with the impairment of certain assets, (iv) and certain other adjustments. From this amount, we then add or subtract an assumed incremental income tax impact on the above-noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measure is useful to investors as a way to analyze the business consistently across the periods presented. This measure is used by our management for the same reason.
•Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count adjusted for anti-dilutive instruments. We believe that this measure is useful to investors as an additional way to analyze the underlying trends in our business consistently across the periods presented. This measure is used by our management for the same reason.
•Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions and divestitures as if those acquisitions and divestitures had occurred on the first day of the trailing 12-month period). We believe that this measure is useful to investors as a way to evaluate and measure the Company’s capital allocation strategies and the underlying trends in the business. This measure is used by our management for the same reason.
•Free cash flow is equal to our cash flows from operating activities, less capital expenditures, plus the direct costs to close acquisitions and divestitures (including income tax effects, if any) in the period. Free cash flow conversion is free cash flow divided by adjusted net income. We believe that these measures are useful to investors as they provide a view on the Company’s ability to generate cash for use in financing or investment activities. These measures are used by our management for the same reason.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.


Forward-Looking and Cautionary Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “assumption,” “believe,” “continue,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “intend,” “likely,” “long-term,” “near-term,” “objective,” “opportunity,” “outlook,” “plan,” “potential,” “project,” “projection,” “prospects,” “seek,” “target,” “trend,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in “Risk Factors” in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.


Avantor, Inc. and subsidiaries
Unaudited condensed consolidated statements of operations
(in millions, except per share data)
Three months ended September 30,
Nine months ended September 30,
2024
2023
2024
2023
Net sales$1,714.4 $1,720.2 $5,097.0 $5,244.4 
Cost of sales1,150.0 1,141.6 3,380.6 3,451.0 
Gross profit564.4 578.6 1,716.4 1,793.4 
Selling, general and administrative expenses439.8 368.4 1,269.7 1,119.5 
Impairment charges— — — 160.8 
Operating income
124.6 210.2 446.7 513.1 
Interest expense, net(48.7)(72.4)(173.9)(219.5)
Loss on extinguishment of debt(2.1)(2.0)(6.5)(5.9)
Other income, net
0.7 0.7 3.4 3.3 
Income before income taxes
74.5 136.5 269.7 291.0 
Income tax expense
(16.7)(28.1)(58.6)(68.4)
Net income
$57.8 $108.4 $211.1 $222.6 
Earnings per share:

Basic$0.08 $0.16 $0.31 $0.33 
Diluted$0.08 $0.16 $0.31 $0.33 
Weighted average shares outstanding:
Basic680.3 676.0 679.3 675.4 
Diluted683.0 678.5 682.1 678.1 





















Avantor, Inc. and subsidiaries
Unaudited condensed consolidated balance sheets
(in millions)September 30, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$285.3 $262.9 
Accounts receivable, net1,087.7 1,150.2 
Inventory779.6 828.1 
Other current assets135.6 143.7 
Assets held for sale216.5 — 
Total current assets2,504.7 2,384.9 
Property, plant and equipment, net722.8 737.5 
Other intangible assets, net3,522.7 3,775.3 
Goodwill, net5,670.6 5,716.7 
Other assets419.8 358.3 
Total assets$12,840.6 $12,972.7 
Liabilities and stockholders' equity
Current liabilities:
Current portion of debt$229.7 $259.9 
Accounts payable673.5 625.9 
Employee-related liabilities183.3 133.1 
Accrued interest39.9 50.2 
Other current liabilities401.7 411.2 
Liabilities held for sale101.7 — 
Total current liabilities1,629.8 1,480.3 
Debt, net of current portion4,691.4 5,276.7 
Deferred income tax liabilities547.3 612.8 
Other liabilities418.9 350.3 
Total liabilities7,287.4 7,720.1 
Stockholders’ equity:
Common stock including paid-in capital3,924.5 3,830.1 
Accumulated earnings
1,702.6 1,491.5 
Accumulated other comprehensive loss
(73.9)(69.0)
Total stockholders’ equity5,553.2 5,252.6 
Total liabilities and stockholders' equity$12,840.6 $12,972.7 

























Avantor, Inc. and subsidiaries
Unaudited condensed consolidated statements of cash flows
(in millions)
Three months ended September 30,
Nine months ended September 30,
2024
2023
2024
2023
Cash flows from operating activities:
Net income
$57.8 $108.4 $211.1 $222.6 
Reconciling adjustments:
Depreciation and amortization102.4 98.0 304.6 

301.7 
Impairment charges— — — 160.8 
Stock-based compensation expense
11.9 9.8 35.7 

31.7 
Non-cash restructuring charges16.4 — 16.4 — 
Provision for accounts receivable and inventory16.3 19.4 55.8 62.5 
Deferred income tax benefit
(22.6)(29.4)(75.3)(94.1)
Amortization of deferred financing costs2.8 3.2 8.6 9.9 
Loss on extinguishment of debt2.1 2.0 6.5 5.9 
Foreign currency remeasurement (gain) loss
(0.1)(3.0)3.0 (3.1)
Changes in assets and liabilities:
Accounts receivable34.2 47.2 34.2 55.1 
Inventory(7.3)10.8 (21.5)9.1 
Accounts payable(4.0)(21.4)41.9 (95.8)
Accrued interest(16.2)(9.7)(16.5)(10.3)
Other assets and liabilities56.6 (4.2)63.0 (38.5)
Other(5.5)(0.4)— 0.9 
Net cash provided by operating activities
244.8 230.7 667.5 618.4 
Cash flows from investing activities:
Capital expenditures(40.8)(37.7)(121.3)(95.8)
Other0.3 0.7 1.7 2.1 
Net cash used in investing activities
(40.5)(37.0)(119.6)(93.7)
Cash flows from financing activities:
Debt repayments(214.3)(197.6)(585.0)(657.9)
Payments of debt refinancing fees and premiums— — — (2.3)
Proceeds received from exercise of stock options16.5 9.4 67.3 14.1 
Shares repurchased to satisfy employee tax obligations for vested stock-based awards(0.8)(0.2)(8.2)(13.5)
Net cash used in financing activities
(198.6)(188.4)(525.9)(659.6)
Effect of currency rate changes on cash and cash equivalents7.9 (5.4)0.6 (1.3)
Net change in cash, cash equivalents and restricted cash13.6 (0.1)22.6 (136.2)
Cash, cash equivalents and restricted cash, beginning of period296.7 260.8 287.7 396.9 
Cash, cash equivalents and restricted cash, end of period$310.3 $260.7 $310.3 $260.7 











Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures
Adjusted EBITDA and Adjusted EBITDA Margin
(dollars in millions, % based on net sales)
Three months ended September 30,
Nine months ended September 30,
2024
2023
2024
2023
$%$%$%$%
Net income
$57.8 3.4 %$108.4 6.3 %$211.1 4.1 %$222.6 4.2 %
Amortization75.4 4.3 %75.4 4.4 %225.6 4.4 %232.7 4.4 %
Loss on extinguishment of debt2.1 0.1 %2.0 0.1 %6.5 0.1 %5.9 0.1 %
Integration-related expenses1
— — %0.2 — %— — %8.3 0.2 %
Restructuring and severance charges2
49.4 2.9 %6.1 0.4 %82.3 1.7 %18.0 0.3 %
Transformation expenses3
17.1 1.0 %— — %46.6 0.9 %— — %
Reserve for certain legal matters4
7.9 0.5 %3.0 0.1 %7.9 0.2 %4.0 0.1 %
Other5
0.4 — %(0.4)— %(0.4)— %(2.2)— %
Impairment charges6
— — %— — %— — %160.8 3.1 %
Income tax benefit applicable to pretax adjustments
(34.9)(2.0)%(23.1)(1.3)%(85.8)(1.7)%(96.7)(1.8)%
Adjusted net income
175.2 10.2 %171.6 10.0 %493.8 9.7 %553.4 10.6 %
Interest expense, net48.7 2.8 %72.4 4.2 %173.9 3.4 %219.5 4.2 %
Depreciation27.0 1.6 %22.6 1.4 %79.0 1.5 %69.0 1.3 %
Income tax provision applicable to Adjusted Net income51.6 3.0 %51.2 2.9 %144.4 2.9 %165.1 3.1 %
Adjusted EBITDA$302.5 17.6 %$317.8 18.5 %$891.1 17.5 %$1,007.0 19.2 %
━━━━━━━━━
1.Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
2.Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. The expenses recognized in 2024 represent costs incurred to achieve the Company’s publicly-announced cost transformation initiative.
3.Represents incremental expenses directly associated with the Company’s publicly-announced cost transformation initiative, primarily related to the cost of external advisors.
4.Represents charges and legal costs in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.
5.Represents net foreign currency (gain) loss from financing activities and other stock-based compensation expense (benefit).
6.Related to impairment of the Ritter asset group.


Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures (continued)
Adjusted Operating Income and Adjusted Operating Income Margin
(dollars in millions, % based on net sales)
Three months ended September 30,
Nine months ended September 30,
2024
2023
2024
2023
$%$%$%$%
Net income
$57.8 3.4 %$108.4 6.3 %$211.1 4.1 %$222.6 4.2 %
Interest expense, net48.7 2.8 %72.4 4.2 %173.9 3.4 %219.5 4.2 %
Income tax expense
16.7 1.0 %28.1 1.6 %58.6 1.2 %68.4 1.3 %
Loss on extinguishment of debt2.1 0.1 %2.0 0.1 %6.5 0.1 %5.9 0.1 %
Other income, net
(0.7)— %(0.7)— %(3.4)(0.1)%(3.3)— %
Operating income
124.6 7.3 %210.2 12.2 %446.7 8.7 %513.1 9.8 %
Amortization75.4 4.3 %75.4 4.4 %225.6 4.4 %232.7 4.4 %
Integration-related expenses1
— — %0.2 — %— — %8.3 0.2 %
Restructuring and severance charges2
49.4 2.9 %6.1 0.4 %82.3 1.7 %18.0 0.3 %
Transformation expenses3
17.1 1.0 %— — %46.6 0.9 %— — %
Reserve for certain legal matters4
7.9 0.5 %3.0 0.1 %7.9 0.2 %4.0 0.1 %
Other5
0.4 — %0.1 — %1.4 — %0.1 — %
Impairment charges6
— — %— — %— — %160.8 3.1 %
Adjusted Operating Income$274.8 16.0 %$295.0 17.1 %$810.5 15.9 %$937.0 17.9 %
━━━━━━━━━
1.Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.
2.Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. The expenses recognized in 2024 represent costs incurred to achieve the Company’s publicly-announced cost transformation initiative.
3.Represents incremental expenses directly associated with the Company’s publicly-announced cost transformation initiative, primarily related to the cost of external advisors.
4.Represents charges and legal costs in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.
5.Represents other stock-based compensation expense (benefit).
6.Related to impairment of the Ritter asset group.



Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures (continued)
Earnings per share
(shares in millions)
Three months ended September 30,
Nine months ended September 30,
2024
2023
2024
2023
Diluted earnings per share (GAAP)
$0.08 $0.16 $0.31 $0.33 
Dilutive impact of convertible instruments— — — — 
Fully diluted earnings per share (non-GAAP)
0.08 0.16 0.31 0.33 
Amortization0.11 0.11 0.33 0.34 
Loss on extinguishment of debt0.01 — 0.01 — 
Integration-related expenses— — — 0.01 
Restructuring and severance charges0.07 0.01 0.12 0.03 
Transformation expenses0.03 — 0.07 — 
Reserve for certain legal matters0.01 — 0.01 0.01 
Other— — — — 
Impairment charges— — — 0.24 
Income tax benefit applicable to pretax adjustments
(0.05)(0.03)(0.13)(0.14)
Adjusted EPS (non-GAAP)$0.26 $0.25 $0.72 $0.82 
Weighted average shares outstanding:
Diluted (GAAP)683.0 678.5 682.1 678.1 
Incremental shares excluded for GAAP— — — — 
Share count for Adjusted EPS (non-GAAP)683.0 678.5 682.1 678.1 
Free cash flow
(in millions)
Three months ended September 30,
Nine months ended September 30,
2024
2023
2024
2023
Net cash provided by operating activities
$244.8 $230.7 $667.5 $618.4 
Capital expenditures(40.8)(37.7)(121.3)(95.8)
Free cash flow (non-GAAP)$204.0 $193.0 $546.2 $522.6 
Adjusted net leverage
(dollars in millions)September 30, 2024
Total debt, gross1
$5,001.6 
Less cash and cash equivalents(285.3)
$4,716.3 
Trailing twelve months Adjusted EBITDA$1,193.2 
Trailing twelve months ongoing stock-based compensation expense43.9 
$1,237.1 
Adjusted net leverage (non-GAAP)3.8  x
━━━━━━━━━
1.Includes $51.4 million of Finance lease liabilities attributed to Clinical Services business and classified as held for sale.







Avantor, Inc. and subsidiaries
Reconciliations of non-GAAP measures (continued)
Net sales by segment
(in millions)September 30,Reconciliation of net sales growth (decline) to organic net sales growth (decline)
Net sales growth (decline)Foreign currency impactOrganic net sales growth (decline)
20242023
Three months ended:
Laboratory Solutions$1,171.5 $1,159.1 $12.4 $5.3 $7.1 
Bioscience Production542.9 561.1 (18.2)1.9 (20.1)
Total$1,714.4 $1,720.2 $(5.8)$7.2 $(13.0)
Nine months ended:
Laboratory Solutions$3,484.3 $3,555.9 $(71.6)$8.9 $(80.5)
Bioscience Production1,612.7 1,688.5 (75.8)3.6 (79.4)
Total$5,097.0 $5,244.4 $(147.4)$12.5 $(159.9)
(dollars in millions, % based on net sales)September 30,Reconciliation of net sales growth (decline) to organic net sales growth (decline)
Net sales growth (decline)Foreign currency impactOrganic net sales growth (decline)
20242023
$$%%%
Three months ended:
Laboratory Solutions$1,171.5 $1,159.1 1.1 %0.5 %0.6 %
Bioscience Production542.9 561.1 (3.2)%0.3 %(3.5)%
Total$1,714.4 $1,720.2 (0.3)%0.4 %(0.7)%
Nine months ended:
Laboratory Solutions$3,484.3 $3,555.9 (2.0)%0.3 %(2.3)%
Bioscience Production1,612.7 1,688.5 (4.5)%0.2 %(4.7)%
Total$5,097.0 $5,244.4 (2.8)%0.2 %(3.0)%
Adjusted Operating Income by segment
(dollars in millions, % represent Adjusted Operating Income margin)
Three months ended September 30,
Nine months ended September 30,
2024
2023
2024
2023
$%$%$%$%
Laboratory Solutions$151.5 12.9 %$159.1 13.7 %$450.7 12.9 %$511.0 14.4 %
Bioscience Production138.1 25.4 %148.2 26.4 %409.0 25.4 %469.9 27.8 %
Corporate(14.8)— %(12.3)— %(49.2)— %(43.9)— %
Total$274.8 16.0 %$295.0 17.1 %$810.5 15.9 %$937.0 17.9 %


Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
+1 805-617-5297
Christina.Jones@avantorsciences.com
Media Contact
Eric Van Zanten
Head of External Communications
Avantor
+1 610-529-6219
Eric.Vanzanten@avantorsciences.com
Source: Avantor and Financial News